In 1971, for the first time, a team of researchers reversed menopause in aging rats by restoring their hypothalamic function. An early prototype of Amberen, as it would turn out.
2012, Los Angeles, CA - In a 12-week randomized, double blind, placebo controlled human clinical study, the subjects in the active group who were taking Amberen demonstrated both statistically and clinically significant reductions of many symptoms of menopause. On the Menopause Specific Quality of Life scale (MenQOL), the active group demonstrated statistically significant symptomatic relief in comparison with placebo group in the Pyschosocial subscale, which includes irritability and anxiety among other symptoms. No serious adverse side effects of Amberen were registered.
2001, Moscow, Russia - In a randomized, double blind, placebo controlled human clinical study Amberen based therapy lowered many characteristics of menopausal symptoms with statistical significance when compared with placebo group. Those symptoms include hot flashes, sleeplessness and muscle and joint pains among others. A clinically important alleviation of low libido, headaches and other symptoms was also observed. No serious adverse side effects of Amberen were registered. The results of this study have been published in several peer-reviewed publications:
· (2008) A Succinate-Based Composition Reverses Menopausal Symptoms Without Sex Hormone Replacement Therapy. Advances in Gerontology, Vol. 21, No. 2, pp. 298-305.
· (2007) A Succinate-Based Compositionâ Rejuvenatesâ Aging Mice and Alleviates Menopausal Symptoms in Women Without Sex Hormone Replacement Therapy. Medline (Gerontology, Endocrinology), Vol. 8, Art. 46, pp. 497-517.
· (2005) Succinate-Based Preparation Alleviates Manifestations of the Climacteric Syndrome in Women. Bulletin of Experimental Biology and Medicine (Pharmacology and Toxicology), Vol. 140, No. 3, pp. 312-314.
2001 to 2004, Russia - In a 3-year long term, multi-center observational clinical study 245 women were treated with Amberen and observed by their physicians. Amberen was âfound to be a highly effective monotherapyâ for treatment of menopausal symptoms. No serious adverse side effects of Amberen were registered.
Amberen is also backed by a comprehensive toxicology dossier, including the studies of acute toxicity, genotoxicity (mutational effects), gravimetrical analysis of the femur tissue, elemental analysis of femoral bone tissue (Ca, Zn, K, Na, Mg), age-related changes to the estrous (ovulation) cycle, etc., that establish the productâs safety.
Succinate as geroprotector in the course of chronological aging. V. A. Samokhvalov, M. N. Kondrashova. Biochimie.
Signal, sympathetic action of succinate in experimental and clinical studies. E. I. Maevsky, A. S. Rosenfeld, A. B. Peskov, M. N. Kondrashova, BBA, Suppl.v.14, 14th EBEC Short Reports, 536-537.
Hormone-like action of amber (succinic) acid. M. N. Kondrashova. Voprosy Biol. Med. Pharmac. Chemistry, Moscow 1, 7-12.
Mechanisms of physiological activity and curative effect of small doses of succinic (amber) acid. M. N. Kondrashova, European Journal of Medicine, Res. 5, 28.
Succinic acid as a physiological signal molecule. In: Signal Molecule and Behaviour. M. N. Kondrashova, S. P. Volkova, I. V. Kuznetzov, Manchester University Press, Manchester & New York, 295-300.
Succinic acid as the only energy support of intensive Ca2+ - uptake by mitochondria. M. N. Kondrashova, V. G. Gogvadze, A. M. Babsky, Bioch. Bioph. Res. Comm. 109, 2, 376-381.
The effect of amber (succinic) system in old rats. V. M. Dilman et al. Pharmacology and Toxicology, Moscow, 3, 540.
Therapeutic action of amber (succinic) acid (M. N. Kondrashova), ONTI Pushchino.
Accumulation and utilization of amber (succinic acid) in mitochondria. M. N. Kondrashova, Nauka, Moscow, 151-169.
If you've been suffering from menopause symptoms without relief in sight, we invite you to try Amberen risk-free. Step away from the stress and discomfort of menopause symptoms — and into a new phase of rejuvenated health and well-being with Amberen.